SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 192.10-1.6%Jan 30 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tdinovo who wrote (7913)9/28/1997 10:08:00 PM
From: Henry Niman   of 32384
 
tdinovo, Usually Biotechs get bought out when they hit a brick wall. Hybritech's diagnostics were doing fine, but therapeutics (which were supposed to be finded by diagnostics) was going nowhere (and still hasn't) and Cetus ran into problems with IL-2 (wasn't as broadly applicable as originally thought).

Actually, the problems of these two Biotcehs turned out to be pluses for LGND. Joe Lacob was in charge of developmennt of the Cetus IL-2 program and he left Cetus and went to Klienner Perkins Caufield & Byers and was my first contact (when starting Progenx, the parent of Ligand). Brook Byers of course became a General Partner because of Hybritech. He also was heavily involved with the formation of Progenx and became Board Chair. He recruited Howard Birndorf as Progenx and Ligand's first President & CEO and Howard had his Biotech roots in Hybritech, as did LGND's current legal council, Larry Respess who probably was heavily involved in the diabetes deal, which I put in the "done deal" category.

LGND is just revving up its engines. I would be extremely surprised by a buyout (Brook Byers is no longer LGND's Board Chair - Kleiner Perkins did most of their distributing of LGND holdings in Dec, 1995).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext